2Anna Liberek,Anna Szaflarska-Poplawska,Maria Korzon,Gra(?)yna (?)uczak,Magdalena Góra-Gebka,Ewa (?)o(s|')-Rycharska,Wanda Bako,Mieczyslawa Czerwionka-Szaflarska.Lamivudine therapy for children with chronic hepatitis B[J].World Journal of Gastroenterology,2006,12(15):2412-2416. 被引量：4
3Bozdayi AM, Uzunalimoglu O, Turkyilmaz AR, et al. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat, 2003, 10:256-265
4Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 2003, 125: 1714-1722
5Cooksley WGE, Piratvisuth T, Lee S-D, et al. Peginterferon α-2a (49KD) : an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat, 2003, 10: 298, 305
6Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol, 2004, 19L: 1276-1282
7Dienstag. JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology, 2003, 124: 105-117
8Perry CM, Javrvis B. Peginterferon alpha 2a (40 × 103) : a review of its use in the management of chronic hepatitis C. Drugs , 2001, 61: 2263, 2288
9Lau CK, Piratvisuth T, Luo KX, et al. Peginterferon alfα-2a, lamivudine, and the combination for HBeAg- positive chronic hepatits B. N Engl J Med, 2005, 35:2682-2695
10Marcellin P, Bonino F, Lau G, et al. The majority of patients with HBeAg-negative chronic hepatitis B treated with Peginterferon alfα-2a (40KD) (Pegasys) sustain responses 2 years post-treatment. The 41^st Annual Meeting of the European Association for the Study of the liver. 2006, Vienna, Austria. A743
1Keefe EB,Dieterich DT,Han SH,et a1.A treatmentalgorithm for the management of chronic hepatitis B virus infection in the United States:2008 update[J].Clin Gastroenterol Hepatol,2008,18(6):1315-1341.
2Swenson PD,Van Geyt C,Alexan der ER,et a1.Hepatitis B virus genotypes and HBsAg subtypes in refugees and injection drug users in the United States determined by LiPA and monoclonal EIA[J].Med Virol,2001,64(3):305-311.
